News

Surviving breast cancer shouldn't mean relinquishing intimacy


 

EXPERT ANALYSIS AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM

Palatin Technologies, the New Jersey company developing the drug, reformulated it into a subcutaneous injection, which did not affect blood pressure in new safety studies. On that basis, Palatin went ahead with a phase IIB trial in 327 premenopausal women with FSAD, HSDD, or both. The company announced positive results last month.

According to a statement, "[the results] demonstrate that women taking bremelanotide showed clinically meaningful and statistically significant increases in the number of satisfying sexual events and also showed clinically meaningful and statistically significant improved measures of overall sexual functioning and distress related to sexual dysfunction, compared to placebo."

There were no blood pressure problems, although some women did quit the drug because of nausea and vomiting of mild to moderate intensity. Palatin intends to launch a phase III trial next year.

Dr. Krychman has disclosed that he is a consultant/advisor for Warner Chilcott, Pfizer, and Sprout.

Pages

Recommended Reading

The Cancer Screening Wars
Breast Cancer ICYMI
Screening Cuts Breast Cancer Deaths by 20%
Breast Cancer ICYMI
Older Women Lived Longer With Radiotherapy After Lumpectomy
Breast Cancer ICYMI
Cardiac Toxicity Not Seen 25 Years after Breast Radiation
Breast Cancer ICYMI
Age Ups Risk of Other Cancers in Breast Cancer Survivors
Breast Cancer ICYMI
ASCO Update Keeps Breast Cancer Survivor Guidelines Intact
Breast Cancer ICYMI
Breast Cancer Mortality Higher in Blacks Than Whites
Breast Cancer ICYMI
Screening Mammograms Overdiagnosed More Than 1 Million Women
Breast Cancer ICYMI
Patients' Worry, Not Risk, Drives Double Mastectomies
Breast Cancer ICYMI
Psoriasis Patients Have Low Rates of Common Cancers
Breast Cancer ICYMI